Abstract
Accurate prediction of human drug safety remains a major challenge for drug development. Species-difference in drug toxicity represents a main reason for the difficulty in the prediction of human drug toxicity with nonhuman animal models. A combined in vitro-in vivo strategy (IVIVS), using human-based in vitro experimental systems to derive humanspecific information, and animal systems for in vivo variables, may lead to a more accurate prediction of human in vivo drug toxicity. The success of IVIVS requires in vitro models with human-specific drug metabolism, appropriate target cell populations, and relevant endpoints. A novel theory, the Target Cell Initiation Theory for drug-induced organ failure (TACIT), is proposed to support the IVIVS. Based on TACIT, toxicity that requires chronic administration and multiple secondary changes may be defined by the evaluation of changes in target cells that initiate the cascade of secondary events. A novel in vitro experimental system, the Integrated Discrete Multiple Organ Co-culture (IdMOC) system, which allows the evaluation of multiple organ toxicity under conditions allowing multiple organ interactions, is described as a promising technology.
Keywords: Species difference, Drug Toxicity, in vitro systems, cytotoxicity, Troglitazone, High content assays
Current Drug Safety
Title: Human-Based In Vitro Experimental Systems for the Evaluation of Human Drug Safety
Volume: 2 Issue: 3
Author(s): Albert P. Li
Affiliation:
Keywords: Species difference, Drug Toxicity, in vitro systems, cytotoxicity, Troglitazone, High content assays
Abstract: Accurate prediction of human drug safety remains a major challenge for drug development. Species-difference in drug toxicity represents a main reason for the difficulty in the prediction of human drug toxicity with nonhuman animal models. A combined in vitro-in vivo strategy (IVIVS), using human-based in vitro experimental systems to derive humanspecific information, and animal systems for in vivo variables, may lead to a more accurate prediction of human in vivo drug toxicity. The success of IVIVS requires in vitro models with human-specific drug metabolism, appropriate target cell populations, and relevant endpoints. A novel theory, the Target Cell Initiation Theory for drug-induced organ failure (TACIT), is proposed to support the IVIVS. Based on TACIT, toxicity that requires chronic administration and multiple secondary changes may be defined by the evaluation of changes in target cells that initiate the cascade of secondary events. A novel in vitro experimental system, the Integrated Discrete Multiple Organ Co-culture (IdMOC) system, which allows the evaluation of multiple organ toxicity under conditions allowing multiple organ interactions, is described as a promising technology.
Export Options
About this article
Cite this article as:
Li P. Albert, Human-Based In Vitro Experimental Systems for the Evaluation of Human Drug Safety, Current Drug Safety 2007; 2 (3) . https://dx.doi.org/10.2174/157488607781668909
DOI https://dx.doi.org/10.2174/157488607781668909 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design Current Understanding of In-stent Restenosis and the Potential Benefit of Drug Eluting Stents
Current Drug Targets - Cardiovascular & Hematological Disorders The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Insight to the Pathophysiology of Stable Angina Pectoris
Current Pharmaceutical Design Role of Platelets in Angiogenesis in Health and Disease
Current Angiogenesis (Discontinued) Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases
Current Topics in Medicinal Chemistry Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology Structure-activity Relationships of Snake Toxins Targeting Platelet Receptors, Glycoprotein Ib-IX-V and Glycoprotein VI
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Involvement of the Mitochondrial Benzodiazepine Receptor in Traumatic Brain Injury: Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Novel Self-micro Emulsifying Drug Delivery System for Safe Intramuscular Delivery with Improved Pharmacodynamics and Pharmacokinetics
Current Drug Delivery Embolic Protection Devices in Saphenous Vein Graft and Native Vessel Percutaneous Intervention: A Review
Current Cardiology Reviews Apoptosis in Atherosclerosis: Virtue or Vice
Current Cardiology Reviews The Action of Prostaglandins on Ion Channels
Current Neuropharmacology Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds Inhaled Dry Powder Formulations for Treating Tuberculosis
Current Drug Delivery Polycation-Based Gene Therapy: Current Knowledge and New Perspectives
Current Gene Therapy Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability
Current Medicinal Chemistry Chronic Tendon Pain: No Signs of Chemical Inflammation but High Concentrations of the Neurotransmitter Glutamate. Implications for Treatment?
Current Drug Targets Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews